Boston Scientific's Off-Label Stent Sales Probed

Law360, New York (February 28, 2008, 12:00 AM EST) -- Boston Scientific Corp.'s annual report to the U.S. Securities and Exchange Commission said Thursday that the Department of Justice is investigating allegations that the company promoted its biliary stents for off-label uses.

Off-label use refers to the application of a product in a way not officially approved by the U.S. Food and Drug Administration. Doctors are free to prescribe off-label uses, but manufacturers cannot promote them.

The Massachusetts-based maker of medical devices reported in its 10K filing for fiscal 2007 that the Department of Justice contacted...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.